SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

08:30am, Thursday, 18'th Feb 2021

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences

08:30am, Tuesday, 09'th Feb 2021

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Why Novartis, Seelos Therapeutics And More Are Moving Today

11:52am, Tuesday, 26'th Jan 2021

Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S.-based

Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine

08:30am, Tuesday, 26'th Jan 2021

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod

11:18am, Thursday, 24'th Dec 2020

The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma

11:30am, Wednesday, 23'rd Dec 2020

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Week In Review: Week's China Life Science Investments Total $800 Million

03:01pm, Sunday, 20'th Dec 2020

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing a

Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies

06:00am, Tuesday, 15'th Dec 2020

SOUTH SAN FRANCISCO, Calif. and BOSTON and SHANGHAI, China, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the developm

Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology

10:00am, Monday, 07'th Dec 2020

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology

10:00am, Sunday, 06'th Dec 2020

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting

12:30pm, Saturday, 05'th Dec 2020

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by